News
IONS
42.93
-2.23%
-0.98
Roche Reports Positive Phase III Data For Investigational IgAN Therapy Sefaxersen
NASDAQ · 1d ago
Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
Seeking Alpha · 1d ago
Ionis Advances IgA Nephropathy Program With Positive Phase 3
TipRanks · 2d ago
Ionis Pharmaceuticals, Inc. Partner Roche Announces Positive Phase 3 IMAgINATION Data for Sefaxersen in IgA Nephropathy
NASDAQ · 2d ago
Roche says Sefaxersen trial shows meaningful reduction in proteinuria
TipRanks · 2d ago
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Barchart · 2d ago
This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Benzinga · 3d ago
Midday Fly By: Meta, Tesla slipping after quarterly reports
TipRanks · 3d ago
Ionis treatment of Dravet syndrome granted FDA orphan status
TipRanks · 3d ago
Netflix downgraded, Tesla upgraded: Wall Street’s top analyst calls
TipRanks · 3d ago
Ionis ranked #1 on Science’s Top Employers list
Barchart · 3d ago
What Ionis Pharmaceuticals Bears Saw Before The Fall
Simply Wall St · 3d ago
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Integra Lifesciences (IART) and vTv Therapeutics (VTVT)
TipRanks · 3d ago
Ionis Pharmaceuticals Price Target Raised to $66.00/Share From $54.00 by BMO Capital
Dow Jones · 3d ago
Ionis Pharmaceuticals Raised to Outperform From Market Perform by BMO Capital
Dow Jones · 3d ago
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66
Benzinga · 3d ago
Ionis Pharmaceuticals Announces FDA Approval of HIBSAGO, Eligible for 10-12% Royalties
NASDAQ · 3d ago
Ionis boosted by FDA approval of hepatitis B therapy
TipRanks · 3d ago
Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia
Seeking Alpha · 3d ago
Analyst Raises Ionis Price Target to $66 on Strong Tryngolza Launch and Undervalued sHTG Opportunity
TipRanks · 3d ago
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.